Schonfeld Strategic Advisors LLC Purchases Shares of 199,400 RxSight, Inc. (NASDAQ:RXST)

Schonfeld Strategic Advisors LLC purchased a new position in RxSight, Inc. (NASDAQ:RXST - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 199,400 shares of the company's stock, valued at approximately $6,855,000. Schonfeld Strategic Advisors LLC owned 0.49% of RxSight as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of RXST. Private Trust Co. NA bought a new position in RxSight in the 4th quarter valued at $34,000. Coppell Advisory Solutions LLC boosted its holdings in RxSight by 108.9% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock worth $44,000 after purchasing an additional 672 shares during the last quarter. Arcadia Investment Management Corp MI bought a new stake in RxSight in the fourth quarter valued at approximately $46,000. Harbor Investment Advisory LLC acquired a new position in shares of RxSight in the fourth quarter valued at approximately $52,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of RxSight in the fourth quarter valued at approximately $69,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Stock Up 3.4 %

Shares of RxSight stock traded up $0.48 during mid-day trading on Wednesday, reaching $14.43. 209,444 shares of the stock traded hands, compared to its average volume of 650,130. The business has a 50-day moving average of $20.09 and a 200 day moving average of $32.14. The stock has a market capitalization of $586.19 million, a PE ratio of -17.48 and a beta of 1.32. RxSight, Inc. has a fifty-two week low of $13.50 and a fifty-two week high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. On average, equities research analysts expect that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RXST has been the topic of several recent analyst reports. Stifel Nicolaus decreased their price target on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $43.00 target price on shares of RxSight in a report on Thursday, April 3rd. Bank of America reiterated an "underperform" rating and set a $22.00 target price (down previously from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. JPMorgan Chase & Co. restated an "underweight" rating and issued a $17.00 target price (down previously from $40.00) on shares of RxSight in a report on Friday, April 4th. Finally, Wells Fargo & Company cut their price objective on RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 3rd. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $37.60.

Insider Buying and Selling

In other news, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the transaction, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 9.36% of the stock is currently owned by company insiders.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.